Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024

Senti Biosciences, Inc.

2024-Q1 EPS reported -$0.26

Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.
Net loss $12.1M ($0.26 per share); R&D expenses rose to $8.8M from $7.1M on manufacturing costs.
SENTI-202 Phase 1 trial for AML on track to dose first patient in Q2 2024; initial efficacy data by year-end 2024.
Pilot trial of SENTI-301A for HCC in China (Celest partnership) expects first patient dosing in Q2 2024.
Presented three abstracts at ASGCT 2024, including novel CAR discovery and engineered synthetic switches.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported first quarter of 2024 results: net income Net loss was $12.1 million, or $0.26 per basic and diluted share, EPS $0.26 per basic and diluted share.

Period: first quarter of 2024
Net income: Net loss was $12.1 million, or $0.26 per basic and diluted share
EPS: $0.26 per basic and diluted share
Result: reported results

Exact text from the filing

Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.